{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:57:34Z","timestamp":1792137454343,"version":"4.4.0"},"reference-count":101,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed\/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (\u2018naked mAbs\u2019) prompted the development of new types of molecules. Antibody\u2013drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I\/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs.<\/jats:p>","DOI":"10.3390\/ijms21218192","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T20:05:25Z","timestamp":1604261125000},"page":"8192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True"],"prefix":"10.3390","volume":"21","author":[{"given":"Mattia","family":"D\u2019Agostino","sequence":"first","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Innorcia","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-6363","authenticated-orcid":false,"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"D\u2019agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., and Gay, F. (2019). Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies. Cancers, 11.","DOI":"10.3390\/cancers11122015"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clml.2017.06.014","article-title":"Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors","volume":"17","author":"Gay","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11899-017-0397-7","article-title":"Novel Immunotherapies for Multiple Myeloma","volume":"12","author":"Boccadoro","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1615\/CritRevImmunol.v19.i3.10","article-title":"Regulation of the complement membrane attack pathway","volume":"19","author":"Morgan","year":"1999","journal-title":"Crit. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/mabs.29670","article-title":"Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer","volume":"6","author":"Meyer","year":"2014","journal-title":"MAbs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy","volume":"124","author":"Babes","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc\u03b3 Receptor\u2013Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., and Ortiz Buijsse, A. (2014). Direct In Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood, 124, Abstract #3474 [ASH 2014 56th Meeting].","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3389\/fimmu.2018.02749","article-title":"Promises and pitfalls in the use of PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Oliva","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.2174\/0929867325666180514114806","article-title":"Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma","volume":"26","author":"Gazzera","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14712598.2018.1544240","article-title":"CD38 as an immunotherapeutic target in multiple myeloma","volume":"18","author":"Bonello","year":"2018","journal-title":"Expert Opin. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","article-title":"Antibody-drug conjugates\u2014A new wave of cancer drugs","volume":"24","author":"Bouchard","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Skaletskaya, A., Setiady, Y.Y., Park, P.U., and Lutz, R.J. (2011). Lorvotuzumab mertansine (IMGN901) immune effector activity and its effect on human NK cells. Cancer Res., 71, Abstract #770 [AACR 2011 102nd Annual Meeting].","DOI":"10.1158\/1538-7445.AM2011-770"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"ScFv antibody: Principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Weisel, K., Asemissen, A.M., Besemer, B., Haenel, M., Blau, I.W., Goerner, M., Ko, Y.-D., D\u00fcrig, J., Staib, P., and Mann, C. (2020). Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. J. Clin. Oncol., 38, Abstract #8508 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8508"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1\u20132a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Krishnan, A.Y., Patel, K.K., Hari, P., Jagannath, S., Niesvizky, R., Silbermann, R.W., Berg, D.T., Li, Q., Allikmets, K., and Stockerl-Goldstein, K. (2020). A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed\/ refractory multiple myeloma (RRMM): Preliminary results. J. Clin. Oncol., 38, Abstract #8539 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8539"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lonial, S., Lee, H.C., Badros, A., Trudel, S., Nooka, A.K., Chari, A., Abdallah, A.-O.A., Callander, N.S., Sborov, D.W., and Suvannasankha, A. (2020). Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs). J. Clin. Oncol., 38, Abstract #8536 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8536"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cohen, A.D., Trudel, S., Lonial, S., Libby, E.N., Lee, H.C., Besemer, B., Facon, T., Nooka, A.K., Callander, N.S., and Chari, A. (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics. J. Clin. Oncol., 38, Abstract #8541 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8541"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lee, H.C., Cohen, A.D., Chari, A., Hultcrantz, M., Nooka, A.K., Callander, N.S., Suvannasankha, A., Badros, A., Libby, E.N., and Trudel, S. (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) and renal impairment. J. Clin. Oncol., 38, Abstract #8519 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8519"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Nooka, A.K., Stockerl-Goldstein, K., Quach, H., Forbes, A., Mateos, M.-V., Khot, A., Tan, A., Abonour, R., Chopra, B., and Rogers, R. (2020). DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol., 38, Abstract #8502 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8502"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Raje, N.S., Jakubowiak, A., Gasparetto, C., Cornell, R.F., Krupka, H.I., Navarro, D., Forgie, A.J., Udata, C., Basu, C., and Chou, J. (2019). Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood, 134, Abstract #1869 [ASH 2019 61st Meeting].","DOI":"10.1182\/blood-2019-121805"},{"key":"ref_46","first-page":"59","article-title":"Interim results from the first phase 1 clinical study of the b-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) cc-93269 in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM)","volume":"4","author":"Costa","year":"2020","journal-title":"HemaSphere"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Mateos, M.-V., Nahi, H., Krishnan, A.Y., van de Donk, N.W.C.J., San-Miguel, J., Oriol, A., Rosi\u00f1ol, L., Chari, A., and Adams, H. (2020). Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (R\/R MM). J. Clin. Oncol., 38, Abstract #100 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.100"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_56","unstructured":"Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., H\u00e1jek, R., Spicka, I., Risse, M.-L., and Asset, G. (2020, January 13). Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (ikema): Interim analysis of a phase 3, randomized, open-label study. Proceedings of the EHA25 Virtual Congress, Late-Breaking Abstract #LB2603."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and Function of the ADP Ribosyl Cyclase\/CD38 Gene Family in Physiology and Pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Endell, J., Boxhammer, R., and Steidl, S. (2014). Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide. Blood, 124, Abstract #5712 [ASH 2014 65th Annual Meeting].","DOI":"10.1182\/blood.V124.21.5712.5712"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Weisel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_64","unstructured":"(2020, October 12). Genmab Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\u2014Genmab A\/S. Available online: https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-european-myeloma-network-and-janssen-achieve."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sonneveld, P., Broijl, A., Gay, F., Boccadoro, M., Einsele, H., Blade, J., Dimopoulos, M.A., Delforge, M., Spencer, A., and Hajek, R. (2019). Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). J. Clin. Oncol., 37, Abstract #TPS8055 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055"},{"key":"ref_66","unstructured":"Janssen Biotech Inc (2020, October 12). DARZALEX\u00ae (Daratumumab) Injection. Full Prescribing Information., Available online: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"ref_68","first-page":"bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): An open-label Phase II study","volume":"134","author":"Chari","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Orlowski, R.Z., Goldschmidt, H., Cavo, M., Martin, T.G., Paux, G., Oprea, C., and Facon, T. (2018). Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs. VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J. Clin. Oncol., 36, Abstract #TPS8055 [ASCO 2018 Annual Meeting].","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and \u2013independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet. Haematol."},{"key":"ref_78","unstructured":"Bristol-Myers Squibb Company Press Release (2020, July 29). Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma Untreated Multiple Myeloma. Available online: https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-reports-primary-results-eloquent-1-study-."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bezman, N.A., Kinder, M., Jhatakia, A.D., Mattson, B.K., Pizutti, D., Thompson, E.W., Capaldi, D.A., Mendonca, M.W., Anandam, A., and Dhar, G. (2018, January 14\u201318). Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models. Proceedings of the Cancer Research; American Association for Cancer Research (AACR), Chicago, IL, USA. Abstract #1727.","DOI":"10.1158\/1538-7445.AM2018-1727"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Abdallah, A.-O.A., Hoffman, J.E., Schroeder, M.A., Jacquemont, C., Li, H., Wang, Y., Van Epps, H., and Campbell, M.S. (2019). SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma. J. Clin. Oncol., 37, Abstract #TPS8054 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8054"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted Therapy With Immunoconjugates for Multiple Myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.HS9.0000560524.63281.bc","article-title":"The anti-bcma antibody-drug conjugate gsk2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an ox40 agonist potentiates in vivo activity","volume":"3","author":"Bhattacharya","year":"2019","journal-title":"HemaSphere"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody\u2013drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Cho, S.-F., Lin, L., Xing, L., Wen, K., Yu, T., Hsieh, P.A., Li, Y., Munshi, N.C., Wahl, J., and Matthes, K. (2019). AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo. Blood, 134, Abstract #135 [ASH 2019 61st Annual Meeting].","DOI":"10.1182\/blood-2019-128528"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clml.2019.09.435","article-title":"Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma","volume":"19","author":"Kim","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(19)30254-6","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma: Another cook in the kitchen?","volume":"7","author":"Mina","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Saltarella, I., Desantis, V., Melaccio, A., Solimando, A.G., Lamanuzzi, A., Ria, R., Storlazzi, C.T., Mariggi\u00f2, M.A., Vacca, A., and Frassanito, M.A. (2020). Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9010167"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Madduri, D., Usmani, S.Z., Jagannath, S., Singh, I., Zudaire, E., Yeh, T.-M., Allred, A.J., Banerjee, A., Goldberg, J.D., and Schecter, J.M. (2019). Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM). Blood, 134, Abstract #577 [ASH 2019 61st Annual Meeting].","DOI":"10.1182\/blood-2019-121731"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing","volume":"26","author":"Zaccaria","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:58Z","timestamp":1760178478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":101,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21218192"],"URL":"https:\/\/doi.org\/10.3390\/ijms21218192","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}